[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@StockwatchDK Stockwatch DK
Stockwatch DK posts on X about price of, activities, cash flow, eli lilly the most. They currently have XX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +84%
Mentions: X #
- X Week XX -XX%
- X Month XXX +138%
Followers: XX #
- X Week XX +44%
- X Month XX +30%
CreatorRank: undefined #
Social Influence #
Social category influence currencies finance stocks
Social topic influence price of, activities, cash flow, eli lilly, make a, has been, favorites, upside
Top assets mentioned Eli Lilly and Company (LLY)
Top Social Posts #
Top posts by engagements in the last XX hours
"Says: We acknowledge the significant uncertainty surrounding rsted's offshore activities in the US but expect the company to at least complete Revolution Wind which should limit the financial risk of further government intervention"
X Link @StockwatchDK 2025-10-10T08:28Z XX followers, XX engagements
"Bernstein says M&A risk could overhang as pro-forma cliff steeper; Genmab will be pro-forma net cash in 2029; maintains Underperform with DKK1015 PT on 6x PE28 discount to peers"
X Link @StockwatchDK 2025-10-09T08:46Z XX followers, XX engagements
"Bernstein reiterates Underperform on Genmab with a target price of 1015 DKK says Merus deal makes strategic sense delaying patent cliff to 2035 if executed well; first-mover advantage in head/neck cancer with high unmet need"
X Link @StockwatchDK 2025-10-09T08:45Z XX followers, XX engagements
"Ahead of the Q3 report SEB has cut its target price on Novo Nordisk to XXX DKK from XXX DKK and keeps Buy but says the upcoming data from the Alzheimer's trials is likely to be the biggest potential swing factor for the stock in the short term"
X Link @StockwatchDK 2025-10-13T21:08Z XX followers, XX engagements
"In a deep dive Danske Bank says that in Q4 XX Novo Nordisk will report data from the evoke and evoke+ trials where semaglutide is being tested for the treatment of early Alzheimers disease. -"
X Link @StockwatchDK 2025-09-24T07:38Z XX followers, XXX engagements
"Says on Genmab: Royalties for Darzalex will likely peak in 2028 and decline until 2031 when they will cease. With good visibility regarding Darzalex and given the tax rate of XX percent it is easy to reach a net present value after tax of approximately DKK 1000 per share"
X Link @StockwatchDK 2025-10-10T08:34Z XX followers, XX engagements
"Says the DKK160 12M target price reflects both current construction risk and no future project wins. From 2028 onwards Danske Bank estimates an underlying annual free cash flow yield of 18%"
X Link @StockwatchDK 2025-10-09T09:48Z XX followers, XX engagements
"IQVIA new-to-brand (NBRx) trends for the starter doses of obesity GLP-1s in the US market for the week ending 3rd October: Total Novo Nordisk GLP-1 NBRx increased +8.5% w/w vs Eli Lilly increased +1.7% w/w (all doses)"
X Link @StockwatchDK 2025-10-13T20:54Z XX followers, XX engagements
"Danske Bank downgrades DFDS to Sell from Hold and reduces the target price to XX DKK from XX DKK expects Q3 to be a weak quarter and says competition will make DFDS make a profit warning"
X Link @StockwatchDK 2025-10-10T08:43Z XX followers, XX engagements
"DSV share price has been under pressure recently to reflect concerns on short term profitability in the context of sequentially weakening freight market backdrop. UBS lowers EBIT estimates FY26/27 by 4-6% to reflect taking a more conservative view on Air and Sea ocean yields.-"
X Link @StockwatchDK 2025-09-25T14:32Z XX followers, XX engagements
"Danske Bank expects rsted to announce farm-downs of Hornsea X and Greater Changhua X and see it capable of handling a worst-case scenario for Revolution and Sunrise Wind. There are still challenges to overcome but Danske Bank also sees value at current levels"
X Link @StockwatchDK 2025-10-09T09:47Z XX followers, XX engagements
"Handelsbanken is making a change to its sector favorites within Healthcare with Getinge becoming one of the sector favorites. Danish Genmab is Handelsbanken's first choice in the sector which means that Novo Nordisk is removed from the list after a return of XX percent"
X Link @StockwatchDK 2025-10-10T08:32Z XX followers, XXX engagements
"But says deal is 50-60% dilutive to 2026-27 EPS accretive only by 2031; Merus won't earn X% WACC until 2030; pro-forma DCF suggests share price discounts best case"
X Link @StockwatchDK 2025-10-09T08:45Z XX followers, XX engagements
"rsted has concluded its DKK60bn rights issue and Danske Bank resumes coverage with a Buy rating and a target price of XXX DKK (vs XXX DKK earlier)"
X Link @StockwatchDK 2025-10-09T09:47Z XX followers, XX engagements
"SEB hikes target price on Jyske Bank to XXX DKK from XXX DKK and reiterates Hold says Jyske Bank is set for a 2025 profit upgrade before Q3 numbers as an underlying slightly better than expected Q3 combined with a substantial trading gain should see profits soar"
X Link @StockwatchDK 2025-10-09T14:52Z XX followers, XX engagements
"Handelsbanken continues to have a positive view on Novo Nordisk with a Buy recommendation but now sees greater risk-adjusted upside in Genmab and Getinge"
X Link @StockwatchDK 2025-10-10T08:33Z XX followers, XXX engagements
"UBS hikes target on Genmab to 2700 DKK from 2600 DKK and keeps Buy rating says company is approaching turning point expects positive Q3'25 numbers driven by Darzalex but the key to the story is still about catalysts-"
X Link @StockwatchDK 2025-10-06T15:09Z XX followers, XX engagements